Results 291 to 300 of about 1,536,180 (350)

Longitudinal Relationship Between Pain and Depression in People With Inflammatory Arthritis: A Narrative Review

open access: yesArthritis Care &Research, EarlyView.
As many patients with inflammatory arthritis (IA) have chronic pain, understanding how to best assess and manage pain in IA is a priority. Comorbid depression is prevalent in adults with IA, affecting 15% to 39% of people. Although pain and depression are thought to be associated in IA, this concept is largely based on cross‐sectional data.
Natasha Cox   +3 more
wiley   +1 more source

Metabolic Consequences of Rheumatoid Arthritis

open access: yesArthritis Care &Research, EarlyView.
Patients with rheumatoid arthritis (RA) may have metabolic disruption, which can contribute to adverse long‐term outcomes, for multiple reasons. Patients with RA appear to have a higher risk of sarcopenia, type 1 and type 2 diabetes mellitus, metabolic syndrome, and hypertension. Systemic inflammation in RA can cause a “lipid paradox,” with reduced low‐
Stevie Barry   +2 more
wiley   +1 more source

Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: A Propensity Score–Matched Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate and compare the risk of hepatotoxicity associated with the use of febuxostat and benzbromarone in patients with gout. Methods New users of febuxostat or benzbromarone with monitoring of liver function at least three times in a year after initiation of the study drugs were identified from an ...
Wenyan Sun   +8 more
wiley   +1 more source

Drug Approval and Drug Effectiveness

Annual Review of Clinical Psychology, 2014
Data on the efficacy and safety of psychiatric medicines should form the foundation of evidence-based treatment practices. The US Food and Drug Administration (FDA) reviews such data in determining whether to approve new treatments, and the published literature serves as a repository for evidence on treatment benefits and harms.
Glen I. Spielmans, Irving Kirsch
openaire   +3 more sources

Drug Approval Highlights for 2003

The Nurse Practitioner, 2004
In the past 12 months, the FDA has approved important new pharmaceutical drugs and devices of particular interest to primary health care providers. The drugs include: Oxytrol (for urinary incontinence), Valtrex (for reducing the risk of heterosexual transmission of genital herpes), Femring (for vaginal delivery of hormone therapy), Uroxatral (for ...
Laustsen, Gary, Wimett, Lynn
openaire   +3 more sources

Approving new drugs

Science, 2017
As the Trump administration takes shape, there is much speculation as to what major changes will be made. A dominant theme of the Trump campaign was to cut through bureaucracy in Washington, D.C., thereby enhancing innovation and bringing new technology to Americans more quickly.
openaire   +3 more sources

Polypharmacology of Approved Anticancer Drugs

Current Drug Targets, 2017
The major drug discovery efforts in oncology have been concentrated on the development of selective molecules that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets. However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents ...
Amelio, Ivano   +4 more
openaire   +5 more sources

Drug Approval and Surveillance

International Journal of Gynecology & Obstetrics, 1980
ABSTRACTThe author proposes that current regulations governing the licensing of drugs, particularly in the United States, need to be changed and replaced by a system of provisional or conditional licensing and increased postmarketing surveillance of drug use.
openaire   +3 more sources

Home - About - Disclaimer - Privacy